GHENT, Belgium, May 27, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announces it will present at the annual Jefferies 2014 Global Healthcare Conference at the Grand Hyatt in New York City on Monday, 2nd June 2014 at 11:30 a.m. EST (05:30 p.m. CET).
The presentation, followed by a Q&A, will be hosted by Dr Edwin Moses, CEO of Ablynx. The presentation will provide an update on the Company's proprietary key clinical assets, its partnered programmes and the outlook for the near term future.
The presentation will be webcast live and can be accessed on the day via this link or the Ablynx website at www.ablynx.com. A replay of the webcast will be available on the Company's website for 30 days following the presentation. To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast.
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has more than 30 programmes in the pipeline and seven Nanobodies at clinical development stage. Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies including AbbVie, Boehringer Ingelheim, Merck & Co, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.
For more information, please contact
Dr Edwin Moses
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
Follow us on Twitter @AblynxABLX
Ablynx media relations Consilium Strategic Communications:
Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
t: +44 203 709 5700
pdf format of the press release http://hugin.info/137912/R/1788913/614744.pdf